Vemurafenib + Cobimetinib for Thyroid Cancer
Trial Summary
The trial does not specify if you need to stop taking your current medications. However, if you are on certain cancer treatments like anti-BRAF or anti-MEK drugs, you may not be eligible to participate.
Vemurafenib, a BRAF inhibitor, has shown promising results in patients with papillary thyroid cancer that have the BRAF(V600E) mutation, leading to partial responses and stable disease. Additionally, the combination of vemurafenib and cobimetinib has improved survival in patients with BRAF V600-mutated melanoma, suggesting potential benefits for similar mutations in thyroid cancer.
12345The combination of Vemurafenib and Cobimetinib has been studied in patients with melanoma and is generally well tolerated, with common side effects including diarrhea, rash, fatigue, swelling, nausea, and vomiting. In a study involving patients with advanced solid tumors, dose-limiting side effects included severe rash and blurred vision, but the treatment was considered manageable.
12678The combination of Vemurafenib and Cobimetinib is unique for thyroid cancer because it targets specific genetic mutations (BRAF V600) that are common in this cancer type, offering a personalized treatment approach. This combination is used off-label, meaning it's not the standard treatment for thyroid cancer, but it has shown promise in improving outcomes for patients with these mutations.
12349Eligibility Criteria
This trial is for patients with high-risk differentiated thyroid carcinoma that has a specific BRAFV600E gene mutation. It's aimed at those preparing for radioactive iodine therapy.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Melanoma
- Melanoma
- Melanoma
- Melanoma
- Melanoma